IDEXX Laboratories supplies diagnostic tests, instrumentation and practice-management software to the veterinary and companion animal markets and presents a high‑margin, compounding‑growth financial profile, with a gross margin of 59.8% and a five‑year diluted EPS CAGR of 15.73%.
The company’s revenue per share has shown durable expansion, with a five‑year revenue‑per‑share CAGR of 10.59% and a level of $45.18 (period end 2023) that reflects long‑term top‑line per‑share growth [EPS Diluted & Revenue per Share].
Operating cash flow has stepped up materially, rising from about $373.3M in 2017 to $906.5M on a trailing‑twelve‑month basis (period end 2023‑12‑31), and operating cash flow exceeded net income in the latest overlapping period ($906.5M OCF vs $895.0M net income), supporting reported margin durability such as a net profit margin of 23.1% (2023) and operating margin of 43.9% (2022) [Strategic Capital Allocation] [Profit Margin Trends].
Capital structure metrics are conservative: interest coverage is about 36.1x and debt‑to‑equity is 0.2335, indicating comfortable debt service capacity.
At the same time, profitability and earnings momentum show near‑term stress. Diluted EPS growth turned negative year‑over‑year at −17.18% (period end 2025‑03‑31) after a recent peak of $13.34 (2024‑03‑31) and a trough of $10.96 (2024‑12‑31), while revenue‑per‑share growth was 8.7% in the most recent observation, creating a disconnect between top‑line per‑share increases and EPS performance [Revenue & EPS Growth] [EPS Diluted & Revenue per Share].
Financing cash outflows deepened to −$878.1M (period end 2024‑12‑31), even as investing outflows moderated to about −$136.2M (period end 2025‑12‑31), which bears watching for impacts on free cash flow and capital returns [Strategic Capital Allocation].
Market multiples are elevated relative to historical ranges, with a trailing P/E around 38.0x (most recent).
Key fundamentals to monitor going forward include revenue‑per‑share growth (five‑year CAGR 10.59% and recent level $45.18), the trajectory of diluted EPS (recent YoY −17.18% and latest EPS $11.05), the relationship of operating cash flow to net income ($906.5M vs $895.0M), margin trends (net margin 23.1%, gross margin 59.8%), ROE (61.8% at 2025‑03‑31) and the size and composition of financing cash flow (recent −$878.1M) [Return on Equity (ROE)] [Earnings Quality Analysis] [Revenue & Net Income] [Price-to-Earnings (PE) Ratio Trend].
The foundation of business quality and long-term value creation
Revenue for IDEXX LABORATORIES INC /DE shows quarter-to-quarter variability with a recent upward move. After $1.00B in 2024-06 and a slight dip to $975.5M in 2024-09, revenue increased to $998.4M in 2025-03 and then to $1.11B in 2025-06. There are notable larger quarterly values earlier in the series, including $2.75B on 2023-12-31 and $1.67B on 2022-12-31, which stand out from the surrounding quarterly amounts.
Net income has generally clustered in the low-to-mid hundreds of millions with intermittent larger quarters. Recent net income was $242.7M in 2025-03 following a $652.3M result in 2024-12 and $235.6M in 2024-03; 2023-12 recorded $408.6M among other quarters around $200–250M. The most recent quarterly revenue was $1.11B. The most recent reported net income was $242.7M.
Why Growth Matters
Consistent revenue and earnings growth are the lifeblood of successful long-term investments. Companies that can grow their top line (revenue) and bottom line (net income) over many years demonstrate they have products or services customers value and are willing to pay for repeatedly.
Revenue Growth shows whether the company is expanding its market reach, gaining market share, or successfully launching new products.Net Income Growth demonstrates the company can convert that revenue into actual profits while managing costs effectively.
Look for steady, sustainable growth rather than erratic spikes. The best businesses compound earnings year after year, creating tremendous value for shareholders over time. Companies that can grow earnings faster than revenue are improving their profitability—a sign of operational excellence and competitive strength.
Year-over-year growth rates for revenue and earnings per share
Reading the Growth Rate Chart
This chart converts the absolute per-share figures into year-over-year percentage changes, making it easy to see whether growth is accelerating, decelerating, or reverting to trend — regardless of the company's absolute size.
Revenue per Share Growth (1-year, split-adjusted) measures how quickly the top line is expanding on a per-share basis. Sustained positive growth signals that the company continues to win customers and grow its addressable market.EPS Diluted Growth (1-year, split-adjusted) measures how quickly earnings are compounding for each shareholder. When EPS growth consistently outpaces revenue growth, operating leverage and margin expansion are at work.
Look for consistency, not just magnitude. A company that reliably grows EPS 10–15% per year is far more valuable than one that alternates between 50% spikes and deep contractions. Negative EPS growth during a period of positive revenue growth is a red flag — costs are rising faster than sales. Quarters where both lines converge near zero or go negative deserve close scrutiny.
How revenue converts to net income for the most recent annual period
Over the period Jan 2023 to Dec 2023, Idexx Laboratories Inc De converts approximately 60¢ of every revenue dollar into gross profit (gross margin: 59.8%).After accounting for operating expenses and taxes and expenses, the company retains 23.1% as net profit margin, resulting in $0.85B in net earnings.
Period Information
Report Type: Annual (10-K)
Period: Jan 2023 to Dec 2023
Analyzing long-term margin stability and competitive positioning
IDEXX LABORATORIES INC /DE shows gross margins that have been broadly stable in recent years, rising slightly to 59.8% in the latest 2023 period from 59.5% in 2022 after a lower mid‑teens decline from the much higher 74.1% recorded in 2010. Net profit margin has trended upward over the dataset, increasing from 12.8% in 2010 to 23.1% in 2023, with steady gains visible between 2018 (17.0%) and 2023 (23.1%). Operating margin is available through 2022 and shows improvement from 38.6% in 2018 to 43.9% in 2022.
Understanding Profit Margins
Between Jan 2023 and Dec 2023, Idexx Laboratories Inc De converts every dollar of revenue through the following stages:
Sustainable competitive advantages reveal themselves through consistently superior profit margins over extended periods. Companies with durable economic moats maintain pricing power and operational efficiency that competitors struggle to match.
A sign of durable competitive advantage is earning sustained higher margins than competitors.Look for margins that remain stable or improve over time, especially during economic downturns. Declining margins may signal increasing competition, pricing pressure, or deteriorating business fundamentals.
Comparing reported earnings to actual cash generation
IDEXX LABORATORIES INC /DE's trailing twelve‑month net income rose to a peak of $1.08B at the 2024-03-31 period, then declined through the rest of 2024 to $887.9M at 2024-12-31 and edged up slightly to $895.0M by 2025-03-31. The most recent quarters show net income below the March 2024 peak, with the latest observation indicating a modest recovery versus the year‑end trough.
Operating cash flow on a TTM basis has trended higher over the multi‑year record provided, with the latest operating cash flow observation of $906.5M at 2023-12-31. In the most recent date where both metrics are available (2023-12-31), operating cash flow ($906.5M) exceeded net income ($845.0M). The latest reported values are: Net Income TTM $895.0M and Operating Cash Flow TTM $906.5M.
The Earnings vs. Cash Flow Gap
Reported earnings (Net Income) doesn't always reflect actual cash generation. Companies use accrual accounting, which recognizes revenue when earned and expenses when incurred—not when cash actually changes hands. This creates timing differences and opportunities for accounting discretion that can mask underlying business health.
Net Income (the "earnings" number) can be influenced by non-cash items like depreciation, stock-based compensation, and changes in accounting estimates.Operating Cash Flow, however, shows the actual cash the business generates from its core operations—a harder number to manipulate.
Trailing Twelve Months
What to Look For
Key Insight: Companies with durable competitive advantages typically show operating cash flow that meets or exceeds net income over time, demonstrating they convert accounting profits into actual cash that can be returned to shareholders or reinvested in the business.
Measuring management's efficiency at generating profits from shareholder capital
IDEXX LABORATORIES INC /DE's trailing twelve‑month return on equity has been in a stable, elevated range over the most recent quarters, rising to 61.8% at the 2025-03-31 quarter from 55.7% at 2024-12-31 and 56.9% at 2023-12-31. Over the last three reported quarters the ROE shows modest upward movement and currently sits in the low‑60% area, representing the most recent consolidation after larger prior swings.
Historically the series shows pronounced volatility: moderate ROE in the 24–39% range across 2010–2013, a period of very large negative ROE in 2016–2018 (reaching −4,083.5% at 2018-12-31), a dramatic rebound to extreme highs in 2019 (peaking at 930.4% on 2019-03-31) and elevated but declining ROE through 2019–2022 (e.g., 290.1% on 2019-06-30 down to 111.6% on 2022-12-31) before the more recent mid‑50s to low‑60s readings. The most recent reported ROE (period end 2025-03-31) was 61.8%.
The Gold Standard of Profitability
Return on Equity (ROE) is a powerful measure of how effectively a company's management is using the money shareholders have invested. Calculated by dividing Net Income by Shareholders' Equity, it reveals how much profit is generated for every dollar of equity capital.
A consistently high ROE (typically above 15-20%) is often the signature of a "quality" business with a durable competitive advantage. It indicates that the company can generate high returns on its own capital, which it can then reinvest at these high rates to compound value over time.
What to Look For:
How the company generates and deploys its cash
IDEXX LABORATORIES INC /DE demonstrates a sustained growth in operating cash flow over the observed period. Operating cash flow increased from approximately $373.3M in 2017 and $385.6M in 2018 to a significantly higher level of $906.5M at the most recent period end (2023-12-31), reflecting an upward trajectory in cash generated from core operations in the later years.
Investing cash flow has persistently been negative, indicating cash outflows across the timeframe shown. It moved from about -$138.7M in 2017 to larger outflows around -$293.0M in 2021, then moderated to -$125.3M in 2023 and -$136.2M at period end 2025-12-31.
Financing cash flow has also been negative throughout and became more pronounced recently. Financing outflows were -$442.0M at period end 2023-12-31 and increased to -$878.1M at period end 2024-12-31. The latest TTM figures are:
Understanding Company Strategy
Capital allocation refers to how management decides to spend and invest the company's cash. Analyzing the three primary categories of cash flow reveals a company's true operational strategy:
What to look for: Is the company bootstrapping (funding growth solely from operating cash)? Are they borrowing to fund aggressive expansion or dividends? Or are they capital raising by issuing new shares, potentially diluting your ownership? A healthy, mature company typically generates strong operating cash, moderately invests in growth, and returns the surplus to shareholders through financing activities.
Trailing Twelve Months
Net assets attributable to each share — the accounting floor of intrinsic value
Why Book Value per Share Matters
Book value per share is the net worth of the company — total assets minus total liabilities — divided by shares outstanding (split-adjusted). It represents the theoretical liquidation value per share if every asset were sold and every liability repaid at balance-sheet carrying values. It is the accounting foundation upon which much of equity valuation is built.
A steadily rising book value per share is one of the most reliable signals of compounding wealth creation. It means the company is retaining earnings and building net worth faster than it is returning capital or eroding it. Warren Buffett famously tracked Berkshire Hathaway's book value per share for decades as his primary measure of intrinsic value growth.
Context is essential. Asset-heavy businesses (banks, manufacturers, utilities) should be judged by book value more directly than asset-light businesses (software, consumer brands), where intangible assets like intellectual property and customer loyalty may far exceed their balance-sheet carrying values. A company trading at a large premium to book value is not necessarily overvalued — it may simply possess competitive advantages that accounting rules do not capture. Conversely, a declining book value per share — especially over multiple years — is a serious warning sign of capital destruction.
How much of the company is financed by debt versus shareholders' equity
Reading the Debt-to-Equity Ratio
The debt-to-equity (D/E) ratio compares total financial debt to shareholders' equity. A ratio of 1.0 means the company has borrowed one dollar for every dollar of equity; a ratio of 2.0 means it has borrowed twice as much as it owns. Financial leverage amplifies both returns and risk: in good times, debt turbocharges equity returns; in bad times, it accelerates losses and can threaten solvency.
Trends matter more than a single number. A rising D/E ratio can mean the company is taking on debt to fund growth — potentially value-creating if returns exceed the cost of capital. But it can also mean equity is being eroded through losses or that the business is borrowing simply to sustain operations. A falling D/E ratio generally reflects strengthening financial health: earnings are being retained, debt maturities are being paid down, or both.
Industry norms vary enormously. Capital-intensive sectors (utilities, real estate, financials) routinely carry high D/E ratios that would be alarming in, say, a technology company. Always compare against sector peers. As a rough rule of thumb, a D/E above 2× in a cyclical business warrants careful scrutiny of interest coverage and refinancing risk.
Short-term liquidity — can the company cover its near-term obligations?
Liquidity: Can the Business Pay Its Bills?
The current ratio is calculated as current assets divided by current liabilities. A ratio of 1.5 means the company has $1.50 of short-term assets — cash, receivables, inventory — for every $1.00 of obligations due within the next twelve months. It is the most direct measure of near-term financial resilience: can the business meet its obligations without needing to raise new capital or sell long-term assets at a discount?
A ratio above 1.0 is generally healthy, meaning current assets exceed current liabilities. A ratio consistently above 2.0 may indicate the company is holding excess cash or inventory that could be deployed more productively. A ratio below 1.0 is a warning sign — the company is relying on future cash generation or external financing to cover its near-term obligations, which is manageable in normal conditions but dangerous during a downturn.
Trends and context matter.A declining current ratio isn't always alarming — highly efficient businesses (e.g., large retailers with reliable daily cash flows) often run leaner balance sheets intentionally. Conversely, a rapidly rising current ratio can signal slowing sales causing inventory to build, or customers taking longer to pay. Always compare the trend against industry peers and cross-reference with the cash flow statement to assess whether the business is genuinely liquid or just holding non-cash current assets.
How much the market is paying for each dollar of company earnings
IDEXX LABORATORIES INC /DE's trailing twelve-month P/E moved from the mid-to-high double digits in earlier years into a pronounced peak at 71.6x at 2021-12-31, then declined through 2022 into the low 30s. A notable inflection occurred at 2023-12-31 when the P/E jumped to 52.5x, after which it contracted back toward the high-30s over the subsequent quarters.
Over the most recent three reported quarters the P/E has been relatively stable: 39.9x at 2024-03-31, 37.7x at 2024-12-31, and 38.0x at 2025-03-31. The most recent P/E ratio was 38.0x.
What Is the PE Ratio?
The Price-to-Earnings (PE) ratio is one of the most widely used valuation metrics in investing. It divides the current stock price by the company's earnings per share (EPS), revealing how much investors are willing to pay for each dollar of earnings. A high PE can signal that the market expects strong future growth, while a low PE may suggest undervaluation—or reflect genuine concerns about the company's prospects.
Context matters:PE ratios vary significantly across industries. High-growth technology companies routinely trade at PE ratios above 30x or 40x, while mature, low-growth sectors like utilities or financials often trade closer to 10–15x. Always compare a company's PE to its own history and its industry peers, not just an absolute number.
What to Look For:
Key Insight:The PE ratio is a snapshot of market sentiment and expectations. Tracking it over time alongside earnings trends reveals whether the market's valuation has expanded or contracted—and whether that change is justified by fundamentals.